



## DETERMINATION OF MERGER NOTIFICATION M/24/052 – VIAINT MEDICAL/KNIGHTSBRIDGE PLASTICS

---

### Section 21 of the Competition Act 2002

### Proposed acquisition by Viant Medical LLC of sole control of Knightsbridge Plastics Inc.

Dated 10 September 2024

---

1. On 27 August 2024, in accordance with section 18(1)(a) of the Competition Act 2002, as amended (the “Act”), the Competition and Consumer Protection Commission (the “Commission”) received a notification of a proposed acquisition whereby Viant Medical LLC (“Viant”) (the “Acquirer”) would acquire sole control of Knightsbridge Plastics Inc (“Knightsbridge”) (the “Target”) (the “Proposed Transaction”).
2. The Proposed Transaction is to be implemented by way of a securities purchase agreement following the execution of a letter of intention (“LOI”) on 19 April 2024 by Knightsbridge, Viant, Water Street Healthcare Partners LLC (“Water Street”), and JLL Partners LLC (“JLL”), and pursuant to which Viant is to acquire 100% of the shares in, and thus sole control of, Knightsbridge.
3. The parties are involved in the following business activities:

#### *The Acquirer – Viant*

- Viant designs, manufactures and supplies components for applications across a variety of industries, including global medical device, pharmaceutical, diagnostics, aerospace, technology, automotive, and construction sectors. Viant primarily provides services in front-end design, development, manufacturing and assembly of custom metal and plastic components for medical device applications.
- In the State, Viant provides services to customers in front-end design, development, manufacturing and assembly of metal and plastic components for medical device and industrial applications.



### *The Target – Knightsbridge*

- Knightsbridge is a contract manufacturer of high-precision injection moulded plastic parts and components for a wide spectrum of applications in the medical device, biomedical/microfluidics, and technology sectors.
  - In the State, Knightsbridge sells plastic components for medical devices, produced and exported from its sole manufacturing and warehousing facilities located in Fremont, California, to customers in various sectors.
4. After examination of the notification, the Commission has concluded that the Proposed Transaction falls within the scope of paragraph 2.1 of the Simplified Merger Notification Procedure Guidelines for assessing certain notifiable mergers or acquisitions under section 18(1)(a) of the Act since:
- two or more of the undertakings involved in the merger/acquisition are active in the same product and geographic market, but their combined market share is less than 15%.<sup>1</sup>
5. In the light of this, the Commission considers that the Proposed Transaction will not substantially lessen competition in any market for goods or services in the State.

### **Ancillary Restraints**

6. The Parties notified no ancillary restraints.

---

<sup>1</sup> The Commission's Simplified Merger Notification Procedure Guidelines can be found [here](#).



Coimisiún um  
Iomaíocht agus  
Cosaint Tomhaltóirí

Competition and  
Consumer Protection  
Commission

### **Determination**

The Competition and Consumer Protection Commission, in accordance with section 21(2)(a) of the Competition Act 2002, as amended, has determined that, in its opinion, the result of the proposed acquisition, whereby Viant Medical LLC would acquire sole control of Knightsbridge Plastics Inc., will not be to substantially lessen competition in any market for goods or services in the State, and, accordingly, that the acquisition may be put into effect.

For the Competition and Consumer Protection Commission

**Ibrahim Bah**

**Director**

**Competition Enforcement and Mergers Division**